Research programme: anticancer antibodies - ARIUS/Xerion
Latest Information Update: 01 Nov 2006
Price :
$50 *
At a glance
- Originator ARIUS Research; Xerion Pharmaceuticals
- Developer Xerion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Nov 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 17 Oct 2002 Preclinical trials in Cancer in USA (unspecified route)